101 results
8-K
EX-1.1
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities is considering any such claim, litigation, arbitration
8-K
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
harbor” provisions of the Private Securities Litigation Reform Act of 1995, and other federal securities laws. Any statements contained herein that do
424B5
STRO
Sutro Biopharma Inc
2 Apr 24
Prospectus supplement for primary offering
4:58pm
, a litigation settlement, employee arrangements or otherwise. In the event that the outstanding options are exercised, or that we make additional issuances … by reference therein and herein contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties … contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995
8-K
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited
8-K
EX-99.1
6rs53j5 iiyrcqpvrn1
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-1.1
1l3q7z m52
9 Feb 24
Other Events
4:27pm
424B5
resn1tllp
9 Feb 24
Prospectus supplement for primary offering
4:25pm
8-K
4f4u4zyco5yfbjxp
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
q6beqq n7ld
21 Nov 23
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
cmvta1xhdy959beeir
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-99.1
80qqa9m h3zh
10 Aug 23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm